MIRA Pharmaceuticals, Inc. - 8-K Summary
Business Context and Reporting Period
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) filed this Current Report on Form 8-K on March 03, 2026. The filing addresses Item 8.01 (Other Events) regarding the completion of Phase 1 clinical dosing for Ketamir-2, a proprietary selective oral NMDA receptor modulator.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical development milestones and does not contain financial statements.
Material Changes and Clinical Progress
- Phase 1 Completion: Dosing is complete for a randomized, double-blind, placebo-controlled study of Ketamir-2 in 56 healthy adult volunteers.
- Safety Profile: No serious adverse events or dose-limiting toxicities were reported. Notably, no clinically significant dissociative or psychotomimetic effects (typically associated with ketamine) were observed.
- Study Design: Included Single Ascending Dose (SAD) cohorts (50 mg to 600 mg) and Multiple Ascending Dose (MAD) cohorts (150 mg to 600 mg daily for five days).
- Next Steps: The Company intends to submit a Phase 2a clinical study to the FDA in the first half of 2026.
Outlook, Risks, and Management Commentary
Management plans to advance Ketamir-2 toward a Phase 2a proof-of-concept study targeting patients with moderate to severe chemotherapy-induced peripheral neuropathy (CIPN). The study aims to generate safety and preliminary efficacy data using validated neuropathic pain assessment tools. The Company also plans to present Phase 1 data at an upcoming scientific meeting. The filing notes that CIPN currently has no FDA-approved therapies specifically indicated for the condition.
Key Facts for Investor Verification
- Confirmation of the database lock and final audited pharmacokinetic and safety analysis results.
- Timeline for the submission of the Phase 2a Investigational New Drug (IND) application to the FDA.
- Details regarding the upcoming scientific meeting where Phase 1 data will be presented.
- Current cash runway and funding status to support the transition to Phase 2a, as financial data is not included in this filing.